Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.835
-0.060 (-6.67%)
At close: Apr 16, 2024, 4:00 PM
0.843
+0.008 (1.01%)
After-hours: Apr 16, 2024, 7:06 PM EDT

Aligos Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
15.5313.914.36000
Revenue Growth (YoY)
11.66%219.04%----
Gross Profit
15.5313.914.36000
Selling, General & Admin
30.6226.4128.5317.9410.013.21
Research & Development
73.0485.08104.1579.8944.0410.46
Operating Expenses
103.66111.49132.6897.8354.0413.66
Operating Income
-88.13-97.58-128.32-97.83-54.04-13.66
Interest Expense / Income
-1.24-1.64-0.1310.55-1.860.27
Pretax Income
-86.88-95.94-128.19-108.38-52.18-13.93
Income Tax
0.80.110.140.160.090
Net Income
-87.68-96.05-128.33-108.54-52.26-13.93
Shares Outstanding (Basic)
64434010211
Shares Outstanding (Diluted)
64434010211
Shares Change
50.51%7.13%299.03%397.62%-81.93%-
EPS (Basic)
-1.36-2.25-3.22-10.87-26.04-1.25
EPS (Diluted)
-1.36-2.25-3.22-10.87-26.04-1.25
Free Cash Flow
-79.02-80.33-116.55-76.33-49.55-8.57
Free Cash Flow Per Share
-1.23-1.88-2.92-7.64-24.69-0.77
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-567.50%-701.66%-2943.82%---
Profit Margin
-564.61%-690.63%-2944.07%---
Free Cash Flow Margin
-508.83%-577.64%-2673.87%---
EBITDA
-85.06-93.91-124.54-94.51-51.74-12.37
EBITDA Margin
-547.74%-675.24%-2857.15%---
Depreciation & Amortization
3.073.683.783.332.31.29
EBIT
-88.13-97.58-128.32-97.83-54.04-13.66
EBIT Margin
-567.50%-701.66%-2943.82%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).